Welcome, Guest
Username: Password: Remember me
Highflyers from all branches including regenerative medicine.
  • Page:
  • 1

TOPIC: Cynata

Cynata 05 Nov 2016 16:31 #7943

  • Old Young Fox
  • Old Young Fox's Avatar Topic Author
  • Offline
  • Expert Boarder
  • Expert Boarder
  • Posts: 101
  • Thank you received: 12
Dear community,

after several analyses i must indicate that this company could be has a bright future,

Later some resons

holdi

Please Log in or Create an account to join the conversation.

holdi

Cynata 07 Nov 2016 08:21 #7952

  • Old Young Fox
  • Old Young Fox's Avatar Topic Author
  • Offline
  • Expert Boarder
  • Expert Boarder
  • Posts: 101
  • Thank you received: 12
Cyp.ax
Price: A$0.68 (07 Nov. 2016)
Market Cap (MM): A$49,5 (€34,85, $38,33)
Operating results June 2016
The consolidated loss of the Group for the financial year, after providing for income tax expense, amounted to $4,939,471 (2015: $3,712,077).



Cynata Therapeutics Limited is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™. The technology is based upon extremely important and versatile stem cells known as mesenchymoangioblasts (MCAs). MCAs are a precursor of mesenchymal stem (or stromal) cells (MSCs) Cynata’s proprietary technology utilizes iPSCs originating from an adult donor as the starting material for generating MCAs and in turn for manufacturing the MSC therapeutic product.
According to Cynata Therapeutics, “The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale.”
Importantly, the cost-savings advantages, consistent cellular product, and unlimited production capacity of the Cymerus technology position Cynata as an attractive manufacturing partner for biopharmaceutical companies pursuing MSC clinical trials. In particular, a consistent cellular product is absolutely essential to establishing consistent clinical findings.

06 Oct. 2016
World first for allogeneic iPSC-derived cell therapy: Cynata gains clinical trial approval from UK regulatory authority
Cynata plans to conduct the Phase 1 clinical trial, which is entitled “An Open-Label Phase 1 Study to Investigate the Safety and Efficacy of CYP-001 for the Treatment of Adults With Steroid-Resistant Acute Graft Versus Host Disease”, at a number of leading clinical centres in the UK and Australia. Additional centres in other jurisdictions are also being considered. The trial will aim to recruit approximately 16 participants who have undergone a bone marrow transplant or similar procedure, and were subsequently diagnosed with steroid-resistant Grade II-IV acute GvHD.
The Company believes that this will be the world’s first clinical trial involving a therapeutic product derived from allogeneic induced pluripotent stem cells (iPSCs).

05 Sept. 2016
Cynata and FUJIFILM Sign Non-binding Development and Commercialisation Term Sheet

If the parties enter into a definitive agreement, Cynata expects it to be finalised in the fourth quarter of 2016.

The term sheet anticipates that, under a definitive agreement, Cynata will grant FUJIFILM an option to an exclusive, worldwide licence to market and sell Cynata’s lead MSC product for prevention and treatment of graft-versus-host disease (GvHD), as well as (a) an option to negotiate a licence for manufacturing those products, and (b) certain rights to Cynata’s proprietary Cymerus™ technology for the prevention and treatment of other diseases.
The term sheet further anticipates that, under a definitive agreement, FUJIFILM will make a direct investment in Cynata by way of the acquisition of Cynata shares to the value of US$3 million.
Notably FUJFILM acquired Cellular Dynamics International, Inc (CDI) in 2015 for $US307m; CDI is a regenerative medicine company, which like Cynata, was also spun out from the University of Wisconsin-Madison.
09 Jun. 2016
Dr. Paul Wotton, who joined Cynata Therapeutics Board of Directors in June, 2016. He was previously President and CEO of Ocata Therapeutics, Inc. (NASDAQ: OCAT) joining the company in July 2014 and managing it through an all-cash take-over by Atellas Pharma valued at $379 million.
09 May 2016
Option agreement signed with apceth.
Earlier today, Cynata announced that it had signed an initial option license agreement with the privately-held German firm apceth GmbH, which involves a global agreement for apceth to develop and commercialize Cynata’s proprietary CymerusTM technology platform for the production of mesenchymal stem cells (MSCs) in conjunction with apceth’s proprietary genetic modification technology. The agreement involved an immediate upfront cash payment, the magnitude of which was undisclosed, and a definitive license is subject to the completion of an initial collaboration project that is slated to conclude later this year. Under the terms of the license, Cynata and apceth are to work together in developing the CymerusTM technology, and apceth is to provide Cynata with additional payments contingent upon the achievement of subsequent milestones. The total amount of these contingent payments could exceed A$40M. In addition, Cynata could receive royalties on net sales of products developed using its manufacturing platform in conjunction with the apceth technology.

Please Log in or Create an account to join the conversation.

holdi

Cynata 07 Nov 2016 08:27 #7953

  • rodney.strongg
  • rodney.strongg's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 1278
  • Thank you received: 18
Is it listed on NASDAQ - Cyn.ax doesn't work.

Please Log in or Create an account to join the conversation.

Cynata 07 Nov 2016 08:33 #7954

  • Old Young Fox
  • Old Young Fox's Avatar Topic Author
  • Offline
  • Expert Boarder
  • Expert Boarder
  • Posts: 101
  • Thank you received: 12
sorry CYP.AX

Please Log in or Create an account to join the conversation.

holdi

Cynata 18 Dec 2016 06:42 #8306

  • Old Young Fox
  • Old Young Fox's Avatar Topic Author
  • Offline
  • Expert Boarder
  • Expert Boarder
  • Posts: 101
  • Thank you received: 12
the view of fujifilm

www.fujifilm.com/innovation/stories/regenerative-medicine/

they bought cdi, with Mr. Slukvin. He is Co-founder of cynata, 2 Mio Shares...


Cynata has the patent licence from Wisconcin University.

www.pathology.wisc.edu/profile/igor-slukvin


They produce the cells at waisman, is a partner of cdi

gmpbio.org/services-and-products/ips-cells/


Management of cynata say fujifilm sign the binding letter End of 2016, 13 days remaining...


but as always do your own due dilligence

Please Log in or Create an account to join the conversation.

holdi

Cynata and fuji film 19 Jan 2017 14:20 #8593

  • Old Young Fox
  • Old Young Fox's Avatar Topic Author
  • Offline
  • Expert Boarder
  • Expert Boarder
  • Posts: 101
  • Thank you received: 12
ASX ANNOUNCEMENT
19 January 2017
Cynata and FUJIFILM Sign Development and Commercialisation Partnership Agreement

Fujifilm takes
A$3.97
million
strategic
equity
stake in
Cynata

Parties to collaborate on the further development and commercialisation of Cynata’s lead
Cymerus™ therapeutic MSC product
CYP - 001 for graft -versus - host disease (GvHD)

Potential future upfront and milestone payments
in excess of A$60 million

Double
-
digit royalties on CYP
-
001 product
net
sales

Strategic relationship for potential future manufacture of CYP
-
001 and certain rights to
other Cynata technology
Melbourne, Australia
;

cynata.com/wp-content/uploads/2017/01/17.01.19.Cynata-FUJIFILM-Sign-Strategic-Partnership-Agreement.pdf

Please Log in or Create an account to join the conversation.

holdi
  • Page:
  • 1
Time to create page: 0.196 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites